The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,964,436 in first-year total cost, median $2,776,920.
Most frequent study sections
- Special Emphasis Panel[ZRG1 AN-P (11)]1
- Special Emphasis Panel[ZRG1 NV-C (10)]1
- Special Emphasis Panel[ZRG1 NV-G (13)]1
Most frequent institutions
- AMPLO BIOTECHNOLOGY, INC.1
- BIOCIRCUIT TECHNOLOGIES, INC.1
- PROTHERA BIOLOGICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes2R44NS124351-04 | SEPULVEDA, PATRICIO | AMPLO BIOTECHNOLOGY, INC., MD | $2,999,358 | ZRG1 |
| 2024 | Line extension and expanded preclinical evidence for Nerve Tape, a sutureless nerve repair coaptation device2R44NS097113-06A1 | CLEMENT, RYAN S | BIOCIRCUIT TECHNOLOGIES, INC., GA | $1,188,158 | ZRG1 |
| 2023 | Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury2R44NS084575-04 | LIM, YOW-PIN | PROTHERA BIOLOGICS, LLC, RI | $2,776,920 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.